Finland-based Kaiku Health Oy and Novartis have expanded their partnership in digital medicine in order to use machine learning to predict symptoms of multiple diseases. The two companies have been collaborating since June 2021 on a project involving the monitoring of patients with melanoma. Using Kaiku’s digital platform, data is collected from cancer patients and then fed back to healthcare workers to help them personalise care. Patients participating in the first project had melanoma and were receiving combination therapies which inhibit the BRAF and MEK proteins.
